Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Feraheme
Ferumoxytol is an intravenous iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. It is a superparamagnetic iron oxide nanoparticle coated with a carbohydrate shell. Ferumoxytol provides a rapid and convenient method for replenishing iron stores, as it can be administered in higher doses and at a faster rate compared to other iron preparations. It is classified as a parenteral iron product.
For the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
Serious hypersensitivity reactions, including anaphylaxis, have been reported with ferumoxytol. These reactions, which may be fatal, can occur during or within minutes after administration. Observe patients for signs and symptoms of hypersensitivity reactions during and after ferumoxytol administration for at least 30 minutes and until clinically stable. Personnel and therapies for the treatment of serious hypersensitivity reactions should be immediately available.
Outcome:
Reduced efficacy of ferumoxytol
Mechanism:
Binding and removal of iron
Outcome:
Decreased absorption of oral iron
Mechanism:
Competition for absorption in the gut
Outcome:
Chelation and reduced absorption of both drugs
Mechanism:
Chemical binding
Most likely new formulation: Oral ferumoxytol formulation (2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of ferumoxytol expanding its indications to include other forms of iron deficiency anemia in the next 5 years.
Iron Replacement Product, Parenteral Iron
Iron Oxide Nanoparticle